论文部分内容阅读
目的探讨糖类抗原19-9(CA19-9)、糖类抗原15-3(CA15-3)和糖类抗原125(CA125)在甲状腺乳头状癌(PTC)中的表达及临床意义。方法采用免疫组化Max Vision两步法检测80例PTC和80例甲状腺良性病变(BTL,包括34例结节性甲状腺肿、26例桥本甲状腺炎和20例滤泡性腺瘤)患者中CA19-9、CA15-3和CA125的表达状况,分析其表达与PTC患者临床病理特征的关系。结果 80例PTC中CA19-9、CA15-3、CA125阳性表达率分别为85.0%、100.0%、43.8%,与BTL相比,差异具有统计学意义(P<0.01)。CA19-9、CA15-3、CA125的表达与患者年龄、性别、瘤结节数目、直径、淋巴结转移及TNM分期无关(P>0.05)。CA19-9、CA15-3、CA125诊断PTC的灵敏度分别为85.0%、100.0%、43.8%,特异度分别为91.3%、36.3%、91.3%。结论 CA19-9、CA153、CA125的表达有助于PTC和BTL的鉴别诊断。
Objective To investigate the expression and clinical significance of carbohydrate antigen 19-9 (CA19-9), carbohydrate antigen 15-3 (CA15-3) and carbohydrate antigen 125 (CA125) in papillary thyroid carcinoma (PTC). Methods The immunohistochemical Max Vision two-step method was used to detect the expression of CA19-C in 80 patients with PTC and 80 patients with benign thyroid lesions (BTL, including 34 cases of nodular goiter, 26 cases of Hashimoto’s thyroiditis and 20 cases of follicular adenoma) 9, CA15-3 and CA125 expression, analysis of its relationship with the clinicopathological features of PTC patients. Results The positive rates of CA19-9, CA15-3 and CA125 in 80 cases of PTC were 85.0%, 100.0% and 43.8%, respectively, which were significantly different from those of BTL (P <0.01). The expression of CA19-9, CA15-3 and CA125 was not related to the age, sex, tumor nodule number, diameter, lymph node metastasis and TNM stage (P> 0.05). The sensitivity of CA19-9, CA15-3 and CA125 in diagnosing PTC was 85.0%, 100.0% and 43.8% respectively, and the specificity was 91.3%, 36.3% and 91.3% respectively. Conclusion The expressions of CA19-9, CA153 and CA125 are helpful to the differential diagnosis between PTC and BTL.